Source: European Medicines Agency (EU) Revision Year: 2025 Publisher: Amphastar France Pharmaceuticals, Usine Saint Charles, Eragny Sur Epte, 60590, France
Baqsimi 3 mg nasal powder in single-dose container.
| Pharmaceutical Form |
|---|
|
Nasal powder in single-dose container (nasal powder). White to practically white powder. |
Each single-dose container delivers nasal powder with 3 mg of glucagon.
For the full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
Glucagon is a hyperglycaemic agent that mobilises hepatic glycogen, which is released into the blood as glucose. Glucagon inhibits the tone and motility of the smooth muscle in the gastrointestinal tract. |
| List of Excipients |
|---|
|
Betadex (E459) |
The single-dose container consists of polyethylene and polypropylene.
The shrink-wrapped tube is comprised of polyethylene and polypropylene containing a desiccant.
Pack sizes of 1 or 2 single-dose containers.
Not all pack sizes may be marketed.
Amphastar France Pharmaceuticals, Usine Saint Charles, Eragny Sur Epte, 60590, France
EU/1/19/1406/001
EU/1/19/1406/002
Date of first authorisation: 16 December 2019
Date of latest renewal: 22 August 2024
| Drug | Countries | |
|---|---|---|
| BAQSIMI | Austria, Canada, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Japan, Lithuania, Netherlands, Poland, Romania, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.